

Supplementary Table S8. Corpus uterine cancer patient characteristics, median survival, and Multivariate Cox Regression Modeling.

Patient Characteristics: Corpus Uteri		LOR	ALP	No Benzo	Overall	P-value
	N	120 (19.0)	40 (6.3)	470 (74.6)	630 (100%)	
Sex	Female	120 (100.0%)	40 (100.0%)	470 (100.0%)	630 (100.0%)	
Grade (Clinical)	I	21 (17.5%)	9 (22.5%)	213 (45.4%)	243 (38.6%)	<.001
	II	21 (17.5%)	8 (20.0%)	104 (22.2%)	133 (21.1%)	
	III	37 (30.8%)	10 (25.0%)	97 (20.7%)	144 (22.9%)	
	IV	9 (7.5%)	3 (7.5%)	6 (1.3%)	18 (2.9%)	
	Not Reported	32 (26.7%)	10 (25.0%)	49 (10.4%)	91 (14.5%)	
Grade (Pathological)	I	23 (19.2%)	9 (22.5%)	213 (45.4%)	245 (39.0%)	<.001
	II	21 (17.5%)	6 (15.0%)	104 (22.2%)	131 (20.8%)	
	III	38 (31.7%)	12 (30.0%)	96 (20.5%)	146 (23.2%)	
	IV	9 (7.5%)	3 (7.5%)	6 (1.3%)	18 (2.9%)	
	Not Reported	29 (24.2%)	10 (25.0%)	50 (10.7%)	89 (14.1%)	
Stage (Clinical)	I	29 (24.2%)	12 (30.0%)	160 (34.0%)	201 (31.9%)	0.043
	II	2 (1.7%)		9 (1.9%)	11 (1.7%)	
	III	2 (1.7%)		9 (1.9%)	11 (1.7%)	
	IV	6 (5.0%)	2 (5.0%)	4 (0.9%)	12 (1.9%)	
	Not Reported	81 (67.5%)	26 (65.0%)	288 (61.3%)	395 (62.7%)	
Stage (Pathological)	I	49 (41.2%)	11 (28.2%)	235 (50.0%)	295 (47.0%)	<.001
	II	8 (6.7%)	2 (5.1%)	25 (5.3%)	35 (5.6%)	
	III	16 (13.4%)	2 (5.1%)	35 (7.4%)	53 (8.4%)	
	IV	14 (11.8%)	5 (12.8%)	15 (3.2%)	34 (5.4%)	
	Not Reported	32 (26.9%)	19 (48.7%)	160 (34.0%)	211 (33.6%)	
Overall Survival Indicator	Alive	48 (40.0%)	19 (47.5%)	296 (63.0%)	363 (57.6%)	<.001
	Dead	72 (60.0%)	21 (52.5%)	174 (37.0%)	267 (42.4%)	
Progression-Free Survival Indicator	No Progression	46 (38.3%)	18 (45.0%)	286 (60.9%)	350 (55.6%)	<.001
	Progression	74 (61.7%)	22 (55.0%)	184 (39.1%)	280 (44.4%)	

Overall Survival (OS)	Median Surv. (95% CI)	Sample: Corpus Uteri	Log Rank P-value
Total	150.5 (123.2, 181.2)	E=267 C=363 T=630	p= <.001
ALP	52.9 (37.5, 123.2)	E=21 C=19 T=40	
LOR	62.9 (42.7, 90.3)	E=72 C=48 T=120	
No Benzo	NR (157.8, NR)	E=174 C=296 T=470	

Progression-Free Survival (PFS)	Median Surv. (95% CI)	Sample: Corpus Uteri	Log Rank P-value
Total	138.3 (108.6, 162.0)	E=280 C=350 T=630	p= <.001
ALP	38.1 (22.1, 113.6)	E=22 C=18 T=40	
LOR	40.6 (23.6, 76.3)	E=74 C=46 T=120	
No Benzo	178.3 (150.1, NR)	E=184 C=286 T=470	

Overall Survival (OS)		
Predictors: Cohort, Clinical Grade, and Clinical Stage		
Cohort	HR (95% CI)	P-value
No Benzo	Ref.	0.0564
ALP	1.497 (0.931 – 2.405)	0.0956
LOR	1.376 (1.021 – 1.854)	0.0362
Progression-Free Survival (PFS)		
No Benzo	Ref.	0.0149
ALP	1.668 (1.051 – 2.646)	0.0298
LOR	1.433 (1.069 – 1.921)	0.0160

E= event, C= censored, T= Total